View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
September 12, 2013

Generic versions of high cholesterol drug Lovaza can be developed, rules judge

A US appeals court ruled on this week that drug companies can develop generic versions of fish oil-derived, high-cholesterol drug Lovaza.

By Heidi Vella

Judge

A US appeals court ruled on this week that drug companies can develop generic versions of fish oil-derived, high-cholesterol drug Lovaza.

Pronova BioPharma Norge, which holds the patent for Lovaza, filed a patent infringement lawsuit in Delaware against Teva Pharmaceuticals USA and Par Pharmaceutical Inc in order to prevent them from bringing out a generic version of the drug, reports Reuters news agency.

Sales of the drug, marketed by GlaxoSmithKline, were $916m in 2011 in the US.

A Delaware judge agreed that patents of Pronova, bought out by German chemicals firm BASF this year, were valid and would be infringed by a generic product.

However, the US Court of Appeals for the Federal Circuit did not agree with the lower court’s ruling and stated that one of the patents was invalid.

Since another expired in March, the appeals court reversed the lower court’s decision.

The company still has the option to appeal the decision at the US Supreme Court.


Image: Sales of the Lovaza were $916 million in 2011 in the US. Photo: courtesy of Jason Morrison.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology